Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Innoviva Inc (INVA)  
$16.08 0.07 (0.43%) as of 4:30 Wed 5/22


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 101,390,000
Market Cap: 1.63(B)
Last Volume: 668,805 Avg Vol: 666,964
52 Week Range: $12.32 - $16.78
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Innoviva is a company with a portfolio of royalties and other healthcare assets. Co.'s royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®. Co. is entitled to royalty payments made by GSK under its agreements that assigned to Theravance Respiratory Company, LLC (TRC), including TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered or developed in the future under the Long-Acting Beta2 Agonist Collaboration Agreement and the Strategic Alliance Agreement with GSK, which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 215,000 664,000
Total Buy Value $0 $0 $2,804,388 $8,468,005
Total People Bought 0 0 1 2
Total Buy Transactions 0 0 5 12
Total Shares Sold 0 0 10,994 10,994
Total Sell Value $0 $0 $153,810 $153,810
Total People Sold 0 0 1 1
Total Sell Transactions 0 0 1 1
End Date 2024-02-22 2023-11-21 2023-05-23 2022-05-23

   
Records found: 704
  Page 18 of 29  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Glaxosmithkline Plc 10% Owner   –       –       •   2012-02-14 4 B $18.12 $1,603,040 I/I 88,468 15,814,421 1.5     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2011-12-09 4 S $21.86 $218,600 D/D (10,000) 186,774     -
   Drazan Jeffrey M Director   –       •      –    2011-11-28 4 S $21.00 $90,153 D/D (4,293) 42,051     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2011-11-28 4 AS $21.00 $420,000 D/D (20,000) 350,673     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2011-11-28 4 OE $8.53 $257,649 D/D 30,205 370,673     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2011-11-20 4 D $22.34 $50,265 D/D (2,250) 245,864     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2011-11-20 4 D $22.34 $56,565 D/D (2,532) 196,774     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2011-11-20 4 D $22.34 $47,383 D/D (2,121) 340,468     -
   Brinkley David L Head of Business Dev.   •       –      –    2011-11-20 4 D $22.34 $42,156 D/D (1,887) 86,661     -
   Winningham Rick E Chief Executive Officer   •       •      –    2011-11-20 4 D $22.34 $138,910 D/D (6,218) 479,688     -
   Glaxosmithkline Plc 10% Owner   –       –       •   2011-11-01 4 B $22.23 $1,298,477 I/I 58,411 15,725,953 1.5     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2011-09-01 4 OE $8.53 $27,493 D/D 3,225 248,114     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2011-08-20 4 D $17.50 $37,100 D/D (2,120) 342,589     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2011-08-20 4 D $17.50 $44,310 D/D (2,532) 199,306     -
   Brinkley David L Head of Business Dev.   •       –      –    2011-08-20 4 D $17.50 $33,058 D/D (1,889) 88,548     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2011-08-20 4 D $17.50 $39,340 D/D (2,248) 244,889     -
   Glaxosmithkline Plc 10% Owner   –       –       •   2011-08-02 4 B $19.71 $2,019,605 I/I 102,466 15,667,542 1.5     -
   Glaxosmithkline Plc 10% Owner   –       –       •   2011-07-21 4 A $0.00 $0 I/I 9,401,499 15,565,076     -
   Levine Arnold J Director   –       •      –    2011-06-17 4 A $0.00 $0 D/D 20,028 73,988     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2011-06-14 4 S $22.94 $326,322 D/D (14,225) 201,838     -
   Drazan Jeffrey M Director   –       •      –    2011-06-07 4 S $23.29 $743,114 D/D (31,907) 46,344     -
   Drazan Jeffrey M Director   –       •      –    2011-06-06 4 S $23.08 $861,900 D/D (37,344) 78,251     -
   Brinkley David L Head of Business Dev.   •       –      –    2011-05-31 4 S $25.65 $1,320,975 D/D (51,500) 90,437     -
   Brinkley David L Head of Business Dev.   •       –      –    2011-05-31 4 OE $9.69 $449,342 D/D 45,441 141,937     -
   Brinkley David L Head of Business Dev.   •       –      –    2011-05-27 4 S $25.31 $1,463,222 D/D (57,812) 96,496     -
  704 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 18 of 29
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us